There are mainly first-generation EGFR inhibitors, such as gefitinib (Iressa) [20] and erlotinib (Taeceva) [21], which have proven to be a successful therapeutic strategy for the treatment of NSCLC [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.